ArticleCureus2026

Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center.

Alfredo Sebastian Golemba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.